Annual CFO
-$2.40 M
+$3.75 M+61.02%
31 March 2024
Summary:
Sonoma Pharmaceuticals annual cash flow from operations is currently -$2.40 million, with the most recent change of +$3.75 million (+61.02%) on 31 March 2024. During the last 3 years, it has risen by +$980.00 thousand (+29.01%). SNOA annual CFO is now -308.52% below its all-time high of $1.15 million, reached on 31 March 2013.SNOA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$354.00 K
+$1.27 M+138.82%
30 September 2024
Summary:
Sonoma Pharmaceuticals quarterly cash flow from operations is currently $354.00 thousand, with the most recent change of +$1.27 million (+138.82%) on 30 September 2024. Over the past year, it has increased by +$1.46 million (+132.07%). SNOA quarterly CFO is now -92.23% below its all-time high of $4.56 million, reached on 30 September 2012.SNOA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$1.51 M
+$1.58 M+51.21%
30 September 2024
Summary:
Sonoma Pharmaceuticals TTM cash flow from operations is currently -$1.51 million, with the most recent change of +$1.58 million (+51.21%) on 30 September 2024. Over the past year, it has increased by +$3.48 million (+69.75%). SNOA TTM CFO is now -211.27% below its all-time high of $1.36 million, reached on 30 June 2013.SNOA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SNOA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.0% | +132.1% | +69.8% |
| 3 y3 years | +29.0% | +208.6% | +65.1% |
| 5 y5 years | +79.5% | +142.1% | +59.7% |
SNOA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +61.0% | at high | +114.5% | at high | +75.5% |
| 5 y | 5 years | at high | +79.5% | -52.5% | +109.9% | at high | +80.2% |
| alltime | all time | -308.5% | +88.3% | -92.2% | +105.2% | -211.3% | +92.2% |
Sonoma Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $354.00 K(-138.8%) | -$1.51 M(-51.2%) |
| June 2024 | - | -$912.00 K(-700.0%) | -$3.10 M(+29.1%) |
| Mar 2024 | -$2.40 M(-61.0%) | $152.00 K(-113.8%) | -$2.40 M(-52.0%) |
| Dec 2023 | - | -$1.10 M(-10.3%) | -$4.99 M(+17.9%) |
| Sept 2023 | - | -$1.23 M(+472.6%) | -$4.24 M(-12.4%) |
| June 2023 | - | -$215.00 K(-91.2%) | -$4.83 M(-21.4%) |
| Mar 2023 | -$6.15 M(+44.8%) | -$2.44 M(+601.4%) | -$6.15 M(+20.5%) |
| Dec 2022 | - | -$348.00 K(-81.0%) | -$5.11 M(+0.4%) |
| Sept 2022 | - | -$1.83 M(+19.4%) | -$5.08 M(+11.5%) |
| June 2022 | - | -$1.53 M(+9.9%) | -$4.56 M(+7.3%) |
| Mar 2022 | -$4.25 M(+25.8%) | -$1.40 M(+327.9%) | -$4.25 M(-1.9%) |
| Dec 2021 | - | -$326.00 K(-75.0%) | -$4.33 M(+32.9%) |
| Sept 2021 | - | -$1.30 M(+6.6%) | -$3.26 M(+41.0%) |
| June 2021 | - | -$1.22 M(-17.1%) | -$2.31 M(-31.6%) |
| Mar 2021 | -$3.38 M(-26.4%) | -$1.48 M(-297.9%) | -$3.38 M(-38.5%) |
| Dec 2020 | - | $746.00 K(-309.0%) | -$5.49 M(-22.4%) |
| Sept 2020 | - | -$357.00 K(-84.4%) | -$7.08 M(-7.1%) |
| June 2020 | - | -$2.29 M(-36.2%) | -$7.62 M(+66.0%) |
| Mar 2020 | -$4.59 M(-60.8%) | -$3.59 M(+327.5%) | -$4.59 M(+22.6%) |
| Dec 2019 | - | -$840.00 K(-6.5%) | -$3.75 M(-28.9%) |
| Sept 2019 | - | -$898.00 K(-221.7%) | -$5.27 M(-33.5%) |
| June 2019 | - | $738.00 K(-126.9%) | -$7.92 M(-32.4%) |
| Mar 2019 | -$11.72 M(-5.8%) | -$2.75 M(+16.2%) | -$11.72 M(-2.5%) |
| Dec 2018 | - | -$2.36 M(-33.4%) | -$12.02 M(+1.7%) |
| Sept 2018 | - | -$3.55 M(+15.9%) | -$11.81 M(+8.7%) |
| June 2018 | - | -$3.06 M(+0.4%) | -$10.87 M(-12.7%) |
| Mar 2018 | -$12.44 M(+52.3%) | -$3.05 M(+41.2%) | -$12.44 M(+2.9%) |
| Dec 2017 | - | -$2.16 M(-17.0%) | -$12.09 M(+6.0%) |
| Sept 2017 | - | -$2.60 M(-43.9%) | -$11.40 M(+9.4%) |
| June 2017 | - | -$4.63 M(+71.9%) | -$10.42 M(+27.6%) |
| Mar 2017 | -$8.17 M(-6.6%) | -$2.69 M(+83.2%) | -$8.17 M(+13.5%) |
| Dec 2016 | - | -$1.47 M(-9.4%) | -$7.19 M(-14.5%) |
| Sept 2016 | - | -$1.62 M(-31.7%) | -$8.41 M(-1.5%) |
| June 2016 | - | -$2.38 M(+38.0%) | -$8.54 M(-2.4%) |
| Mar 2016 | -$8.75 M | -$1.72 M(-36.0%) | -$8.75 M(-9.4%) |
| Dec 2015 | - | -$2.69 M(+53.9%) | -$9.65 M(+20.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | -$1.75 M(-32.4%) | -$8.02 M(+1.1%) |
| June 2015 | - | -$2.58 M(-1.7%) | -$7.93 M(+18.5%) |
| Mar 2015 | -$6.69 M(+36.9%) | -$2.63 M(+149.3%) | -$6.69 M(+20.5%) |
| Dec 2014 | - | -$1.05 M(-36.6%) | -$5.55 M(+2.0%) |
| Sept 2014 | - | -$1.66 M(+23.6%) | -$5.45 M(+5.1%) |
| June 2014 | - | -$1.35 M(-9.6%) | -$5.18 M(+5.9%) |
| Mar 2014 | -$4.89 M(-525.2%) | -$1.49 M(+57.2%) | -$4.89 M(+10.0%) |
| Dec 2013 | - | -$947.00 K(-32.2%) | -$4.45 M(-3.3%) |
| Sept 2013 | - | -$1.40 M(+32.2%) | -$4.60 M(-438.7%) |
| June 2013 | - | -$1.06 M(+1.2%) | $1.36 M(+18.0%) |
| Mar 2013 | $1.15 M(-128.5%) | -$1.04 M(-4.9%) | $1.15 M(+30.7%) |
| Dec 2012 | - | -$1.10 M(-124.1%) | $880.00 K(+20.9%) |
| Sept 2012 | - | $4.56 M(-460.4%) | $728.00 K(-115.3%) |
| June 2012 | - | -$1.26 M(-3.8%) | -$4.77 M(+18.2%) |
| Mar 2012 | -$4.03 M(-9.0%) | -$1.31 M(+5.1%) | -$4.03 M(+44.4%) |
| Dec 2011 | - | -$1.25 M(+33.1%) | -$2.79 M(-12.1%) |
| Sept 2011 | - | -$939.00 K(+77.5%) | -$3.17 M(-8.3%) |
| June 2011 | - | -$529.00 K(+614.9%) | -$3.46 M(-21.8%) |
| Mar 2011 | -$4.43 M(-33.3%) | -$74.00 K(-95.5%) | -$4.43 M(-24.8%) |
| Dec 2010 | - | -$1.63 M(+33.0%) | -$5.89 M(-1.9%) |
| Sept 2010 | - | -$1.23 M(-17.8%) | -$6.01 M(-6.7%) |
| June 2010 | - | -$1.49 M(-2.9%) | -$6.44 M(-3.0%) |
| Mar 2010 | -$6.64 M(-60.6%) | -$1.54 M(-11.9%) | -$6.64 M(-9.6%) |
| Dec 2009 | - | -$1.75 M(+5.1%) | -$7.34 M(-13.9%) |
| Sept 2009 | - | -$1.66 M(-1.9%) | -$8.52 M(-27.5%) |
| June 2009 | - | -$1.69 M(-24.4%) | -$11.76 M(-30.1%) |
| Mar 2009 | -$16.83 M(-3.5%) | -$2.24 M(-23.5%) | -$16.83 M(-6.7%) |
| Dec 2008 | - | -$2.93 M(-40.2%) | -$18.05 M(-6.1%) |
| Sept 2008 | - | -$4.90 M(-27.6%) | -$19.23 M(+2.7%) |
| June 2008 | - | -$6.77 M(+95.7%) | -$18.72 M(+7.3%) |
| Mar 2008 | -$17.45 M(-3.5%) | -$3.46 M(-15.8%) | -$17.45 M(+24.7%) |
| Dec 2007 | - | -$4.11 M(-6.5%) | -$13.99 M(+41.5%) |
| Sept 2007 | - | -$4.39 M(-20.0%) | -$9.88 M(+80.0%) |
| June 2007 | - | -$5.49 M | -$5.49 M |
| Mar 2007 | -$18.08 M(-11.9%) | - | - |
| Mar 2006 | -$20.52 M(+51.6%) | - | - |
| Mar 2005 | -$13.53 M | - | - |
FAQ
- What is Sonoma Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Sonoma Pharmaceuticals?
- What is Sonoma Pharmaceuticals annual CFO year-on-year change?
- What is Sonoma Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sonoma Pharmaceuticals?
- What is Sonoma Pharmaceuticals quarterly CFO year-on-year change?
- What is Sonoma Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Sonoma Pharmaceuticals?
- What is Sonoma Pharmaceuticals TTM CFO year-on-year change?
What is Sonoma Pharmaceuticals annual cash flow from operations?
The current annual CFO of SNOA is -$2.40 M
What is the all time high annual CFO for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals all-time high annual cash flow from operations is $1.15 M
What is Sonoma Pharmaceuticals annual CFO year-on-year change?
Over the past year, SNOA annual cash flow from operations has changed by +$3.75 M (+61.02%)
What is Sonoma Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of SNOA is $354.00 K
What is the all time high quarterly CFO for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals all-time high quarterly cash flow from operations is $4.56 M
What is Sonoma Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, SNOA quarterly cash flow from operations has changed by +$1.46 M (+132.07%)
What is Sonoma Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of SNOA is -$1.51 M
What is the all time high TTM CFO for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals all-time high TTM cash flow from operations is $1.36 M
What is Sonoma Pharmaceuticals TTM CFO year-on-year change?
Over the past year, SNOA TTM cash flow from operations has changed by +$3.48 M (+69.75%)